Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
Locatelli, Franco
Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. [electronic resource] - The Lancet. Haematology Oct 2018 - e450-e461 p. digital
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
2352-3026
10.1016/S2352-3026(18)30153-4 doi
Adolescent
Brentuximab Vedotin
Child
Child, Preschool
Female
Hodgkin Disease--drug therapy
Humans
Immunoconjugates--therapeutic use
Lymphoma, Large-Cell, Anaplastic--drug therapy
Male
Recurrence
Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. [electronic resource] - The Lancet. Haematology Oct 2018 - e450-e461 p. digital
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
2352-3026
10.1016/S2352-3026(18)30153-4 doi
Adolescent
Brentuximab Vedotin
Child
Child, Preschool
Female
Hodgkin Disease--drug therapy
Humans
Immunoconjugates--therapeutic use
Lymphoma, Large-Cell, Anaplastic--drug therapy
Male
Recurrence